Black Diamond Therapeutics (Nasdaq:BDTX) announced that CEO Mark Velleca, M.D., Ph.D., will join a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026, from 4:55–5:25 p.m. ET. A live and archived webcast will be available.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BDTX
-35.77%4.8x vol
74 alerts
-35.77%Session close to close
-32.5%Trough in 11 hr 34 min
$203.42MMarket Cap
4.8xRel. Volume
In the May 22 session, BDTX declined 35.77%, reflecting a significant negative market reaction.
Argus tracked a trough of -32.5% from its starting point during tracking.
Our momentum scanner triggered 74 alerts that day, indicating high trading interest and price volatility.
Trading volume was very high at 4.8x the daily average, suggesting heavy selling pressure.
The stock dropped -35.8% in the session following this news. A negative reaction despite a routine c...
Analysis
The stock dropped -35.8% in the session following this news. A negative reaction despite a routine conference-participation update fits past patterns, such as the Mar 2 conference announcement that saw a -5.35% move. The market has historically reserved stronger enthusiasm for concrete clinical or financial milestones. With an effective $500,000,000 shelf and $150,000,000 ATM capacity in place, investors may also be sensitive to potential future equity issuance when sentiment softens.
Key Figures
Conference date:June 3, 2026Presentation time:4:55-5:25pm ETWebcast archive duration:90 days
3 metrics
Conference dateJune 3, 2026Jefferies Global Healthcare Conference fireside chat
Presentation time4:55-5:25pm ETScheduled window for Jefferies fireside chat
Webcast archive duration90 daysReplay availability following the Jefferies event
Notified investors of multiple upcoming conference presentations and meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
BDTX has generally reacted positively to clinical and ASCO-related updates, while earnings and conference-participation headlines have produced mixed or negative moves.
Recent Company History
Over the last six months, Black Diamond has highlighted advancing Phase 2 data for silevertinib in NSCLC and GBM and maintained a cash runway into 2H 2028. Clinical and ASCO-linked disclosures on Mar 16, Apr 21, and May 19 all saw positive price reactions. In contrast, earnings updates on Mar 16 and May 7 and a prior conference-participation announcement on Mar 2 drew muted to negative reactions. Today’s Jefferies participation fits the recurring pattern of investor-relations focused news alongside more data-driven catalysts.
Key Terms
oncology, oncogenic mutations, webcast
3 terms
oncologymedical
"Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing..."
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.
oncogenic mutationsmedical
"developing MasterKey therapies that target families of oncogenic mutations in patients..."
Oncogenic mutations are changes in a cell's DNA that push the cell to grow and divide uncontrollably, transforming a normal cell toward cancer. They matter to investors because pinpointing which mutations cause disease guides the creation of targeted drugs, diagnostics and tests — similar to finding the exact broken part in a machine so a company can build a precise repair with clear market and regulatory value.
webcasttechnical
"The Webcast will be available at the start of the presentation under “Events and Presentations”..."
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.
Presentation details are as follows:
4:55-5:25pm ET on Wednesday, June 3
The Webcast will be available at the start of the presentation under “Events and Presentations” on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.
When will Black Diamond Therapeutics (BDTX) present at the Jefferies Global Healthcare Conference 2026?
Black Diamond Therapeutics will present at the Jefferies Global Healthcare Conference on June 3, 2026, from 4:55–5:25 p.m. ET. According to the company, this session will feature a fireside chat with CEO Mark Velleca in New York.
Who will represent Black Diamond Therapeutics (BDTX) at the Jefferies Global Healthcare Conference fireside chat?
Black Diamond Therapeutics will be represented by its Chief Executive Officer, Mark Velleca, M.D., Ph.D., in the fireside chat. According to the company, he will discuss the business on June 3, 2026, at the Jefferies Global Healthcare Conference in New York.
How can investors watch the Black Diamond Therapeutics (BDTX) Jefferies conference webcast?
Investors can watch the live webcast under “Events and Presentations” in the Investors section of Black Diamond Therapeutics’ website. According to the company, the webcast will start at the presentation time and be accessible online without listed geographic restrictions.
Will a replay of Black Diamond Therapeutics’ (BDTX) Jefferies Global Healthcare Conference presentation be available?
Yes, a replay of the webcast will be available and archived for 90 days following the event. According to the company, investors can access this replay in the Investors section of its website under the “Events and Presentations” page.
Is Black Diamond Therapeutics (BDTX) hosting one-on-one investor meetings at the Jefferies Global Healthcare Conference?
Yes, Black Diamond Therapeutics will host one-on-one meetings with investors on June 3, 2026, alongside its fireside chat. According to the company, these meetings will occur the same day as the scheduled conference presentation in New York.
Where is the Jefferies Global Healthcare Conference session for Black Diamond Therapeutics (BDTX) being held?
The Black Diamond Therapeutics session at the Jefferies Global Healthcare Conference will take place in New York, NY, on June 3, 2026. According to the company, the presentation is scheduled from 4:55–5:25 p.m. ET with an accompanying webcast.
